GlassScriptPhysician profile
Kristen M Teixeira
NPI 1760016638
$18,407.04
in general payments reported to CMS, 2019-2025
28 companies · $4,086 in 2025
The $4,086 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,173 · 2022: $3,532 · 2023: $3,441 · 2024: $5,176 · 2025: $4,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,963 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,020 · Consulting Fee: $1,000 · Education: $566 · Travel and Lodging: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,962.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,020.00 |
| Consulting Fee | $1,000.00 |
| Education | $565.72 |
| Travel and Lodging | $154.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,714.91 | 2021-2025 | Tremfya |
| Abbvie INC. | $2,452.88 | 2021-2025 | |
| Incyte Corporation | $2,182.74 | 2021-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $1,700.82 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $1,255.37 | 2021-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $1,245.81 | 2021-2025 | |
| Lilly USA, LLC | $948.46 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $698.58 | 2021-2025 | Siliq, Arazlo, Cabtreo |
| Dermavant Sciences, INC. | $678.63 | 2022-2024 | Vtama |
| Leo Pharma INC. | $594.01 | 2021-2025 | Adbry |
| Pfizer INC. | $582.73 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $556.68 | 2021-2024 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $487.08 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Amgen INC. | $399.05 | 2023-2025 | Otezla, Otezla, Enbrel |
| Allergan, INC. | $340.05 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $293.64 | 2021-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $276.90 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.35 | 2022-2025 | Spevigo |
| Mayne Pharma Commercial LLC | $162.59 | 2021-2024 | |
| Genzyme Corporation | $147.39 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $133.10 | 2021-2023 | Tremfya |
| Organon LLC | $106.15 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $93.98 | 2021 | |
| Kyowa Kirin, INC. | $75.75 | 2021-2023 | Poteligeo |
| Epi Health, LLC | $39.15 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $30.85 | 2023 | Ycanth |
| Sandoz INC. | $17.56 | 2024 | Hyrimoz |
| Lnhc, INC | $15.83 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Teixeira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.